The objective response rates are limited to about 25% (Hirsch et al, 2019), whereas subgroups such as epidermal growth factor receptor (EGFR) or ALK-mutated NSCLC patients hardly benefit from the treatment (Koyama et al, 2016). Here, EGFR is linked to non-small cell lung carcinoma.